Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke
Muriel J Caslake* and Chris J Packard
Correspondence *Department of Vascular Biochemistry, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK
Email m.caslake@clinmed.gla.ac.uk
Risk factors identified by the Framingham Heart Study are useful for assessing a person's risk of cardiovascular disease; however, additional risk factors are needed. In this review, the potential role of lipoprotein-associated phospholipase A2 as a novel inflammatory marker for cardiovascular risk assessment is discussed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Inhibition of lipoprotein-associated phospholipase A 2 reduces complex coronary atherosclerotic plaque developmentNature Medicine Article (01 Oct 2008)
Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: Effect of long-term therapy with erythropoietinKidney International Original Article
See all 9 matches for Research
